GlassScriptPhysician profile
Christopher P Wilson
NPI 1093886178
$3,401.42
in general payments reported to CMS, 2019-2025
16 companies · $1,559 in 2025
The $1,559 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $585 · 2024: $1,257 · 2025: $1,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,401.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $721.72 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $365.94 | 2024-2025 | Spravato, Invega Sustenna, Risperdal |
| Abbvie INC. | $341.76 | 2023-2025 | Vraylar |
| Alkermes, INC. | $284.23 | 2023-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $274.05 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $265.34 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $258.14 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Vanda Pharmaceuticals INC. | $211.54 | 2025 | Fanapt |
| Corium, LLC | $146.90 | 2023-2024 | Azstarys |
| Tris Pharma INC | $122.24 | 2024-2025 | Dyanavel Xr |
| Lundbeck LLC | $108.65 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $85.28 | 2023-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $71.60 | 2024-2025 | Ingrezza |
| Bausch Health US, LLC | $65.20 | 2024-2025 | Aplenzin |
| Collegium Pharmaceutical, INC. | $42.76 | 2025 | Jornay Pm |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $36.07 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.